Biden administration reports in no rush to allow drug imports into Canada
The Biden administration said Friday it did not have a timeline for allowing states to import drugs from Canada, an effort that was approved under President Donald Trump as a key strategy to control costs.
Six states have passed laws to launch such programs, and Florida, Colorado, and New Mexico are furthest along in their plans for federal approval.
The Biden administration said states still had several hurdles to overcome, including a review by the Food and Drug Administration, and that such efforts could face pressure from the Canadian government, which has warned its pharmaceutical industry to do nothing. do that could cause drug shortages in this country.
âAlthough two proposals have been submitted to the FDA, there is no timeline for the agency to make a decision. Thus, the possible future injuries of the plaintiffs’ members are too speculative and not imminent, âthe Biden administration wrote in a court filing Friday night seeking to dismiss a lawsuit from Pharmaceutical Research and Manufacturers of America, a US-based trade group. industry. The drugmakers are asking the court to overturn the rule established by the Department of Health and Human Services in October that, for the first time, allowed states to import drugs from Canada.
The Biden administration said the lawsuit was moot because it is not known when or if states would get an import plan approved.
Importing drugs has been hotly debated for decades, with many states and supporters believing it would help lower the prices Americans pay while the pharmaceutical industry claims it will compromise the security of drug supply to states. -United. Critics note that most brand name drugs sold in the United States are manufactured overseas.
Friday’s court filing was eagerly awaited, as it was the first time the Biden administration had intervened on the matter. Promises to curb high drug prices have been a part of its standard political campaigning, and import benefits broad public support. Supporters of the import range from the political spectrum of Progressive Senator Bernie Sanders (I-Vt.) To conservative Republican Florida Gov. Ron DeSantis. They argue that Americans shouldn’t pay more for drugs than consumers in other countries.
Rachel Sachs, a health law expert at Washington University in St. Louis, said the rhetoric in the court record is likely “disheartening” for DeSantis and other supporters hoping the import programs states would soon be approved. âThey explain that there is no time limit for the FDA and that there are many steps states must take before approval,â she said.
Supporters of the drug importation say they still have hope, especially if the court accepts the administration’s efforts to dismiss the complaint.
“While articulating possible obstacles that could prevent national drug importation programs from moving forward, Biden administration’s motion to dismiss PhRMA lawsuit allows more Americans to benefit from drug importation Said Gabriel Levitt, president of Pharmacychecker.com, which checks online foreign pharmacies for customers.
Importing drugs from Canada, where government controls keep prices low, has been debated for decades in the U.S. A 2003 federal law gave permission for the executive to do so, but only if it is certified as safe and cost effective by the secretary of HHS. Then-secretary Alex Azar announced in September that he would become the first to do so, and the department released its regulations in October.
Florida, Colorado, Maine, New Hampshire, New Mexico and Vermont continue their efforts to import drugs.
PhRMA filed his complaint in November in U.S. District Court for the District of Columbia. In the court filing Friday night, the Biden administration said the FDA could reject state import plans for a number of reasons, including safety concerns and lack of significant savings for consumers.
In an emailed statement, PhRMa spokeswoman Nicole Longo said, âWe continue to believe that the Trump administration violated federal law when it finalized its rule allowing the importation of sponsored drugs. state from Canada without proper certification and in so doing, endangering the health and safety of Americans. ”
Canada has opposing efforts to send its drugs to the United States, fearing that the shortages could be made worse there. Last year, Canadian health regulators informed companies against the export of any drug that could lead to shortages.
During the presidential campaign, Joe Biden supported the importation of drugs. Its HHS secretary, Xavier Becerra, voted for Canada’s 2003 Drug Importation Act as a member of Congress.
In most cases, the FDA says it is illegal for individuals to import drugs for personal use.
Yet for nearly 20 years, storefronts in Florida have helped people buy drugs online from drugstores in Canada and other countries at typically half the price in the United States. The FDA has regularly cracked down on operators but allowed stores to remain open.
The Florida legislature approved the National Drug Import Program in 2019, and the state submitted its proposal to the federal government last year. While DeSantis bragged about the strategy during press conferences in the retirement community of The Villages, the state program would have little direct effect on most Floridians.
Indeed, state efforts are aimed at providing lower-cost drugs to state agencies for prison health programs and other needs and to Medicaid, the federal health program for the poor. Medicaid registrants already pay little or nothing for drugs.
Florida has identified about 150 drugs – many of which are expensive drugs for HIV / AIDS, diabetes and mental health – that it plans to import. Insulin, one of the most expensive drugs widely used, is not included in the program.
DeSantis said the import plan would save the state between $ 80 million and $ 150 million. The state has a budget of $ 96 billion, he said.
âThis has been sufficiently reviewed,â DeSantis said Friday, hours before the filing of the case by the Biden administration. âWe followed all the regulations. We have met all the requirements that we were asked to meet and now we want to be able to get that final approval so that we can finally move forward.
Christina Pushaw, spokesperson for DeSantis, said the governor was disappointed with Biden’s court filing.
“Governor DeSantis calls on the Biden administration to step back from innovation and act immediately to approve Florida’s plan that provides safe and effective drugs to lower prescription costs,” she said in a statement. e-mail addressed to KHN.
The governor reported to LifeScience Logistics in Lakeland, Florida, where state regulators worked with the company to build an FDA-compliant warehouse to process pharmaceuticals from Canada.
âWe’re ready, willing and able, and I think that could be really, really important,â DeSantis said.
He said the warehouse could start receiving drugs from Canada within 90 days if the state gets approval from Washington.
LifeScience Logistics officials said they were working with Methapharm Specialty Pharmaceuticals, which has offices near Toronto and Fort Lauderdale, Fla., To act as a Canadian wholesaler. Quality checks would be performed on drugs in Canada and again in Florida, said Richard Beeny, CEO of LifeScience Logistics.
LifeScience has entered into preliminary price negotiation discussions with drug makers who would deliver drugs to Methapharm, which in turn would ship drugs to the Lakeland warehouse. âThere is a lot of interest in the program,â Beeny said of pharmaceutical companies wishing to participate. “But the pending lawsuit is a bit of a roadblock, so we have to wait and see how it goes.”
Unlike Florida’s plan, Colorado’s Canadian Import Program would help individuals purchase the drugs at their local pharmacy. Colorado would also give health insurance plans the ability to include imported drugs in their benefit designs.
Mara Baer, ââa health consultant who worked with Colorado on its proposal, said the Biden decision left open the question of whether states’ import plans could possibly be approved. “HHS could have dropped the rule and they didn’t, which is important given the challenges Congress faces in advancing major drug pricing reform in the short term,” she said. declared.
Contact Us Submit a Story